BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Meunier S, Alamelu J, Ehrenforth S, Hanabusa H, Abdul Karim F, Kavakli K, Khodaie M, Staber J, Stasyshyn O, Yee DL, Rageliene L. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A. Thromb Haemost 2017;117:1705-13. [PMID: 28692108 DOI: 10.1160/TH17-03-0166] [Cited by in Crossref: 31] [Cited by in F6Publishing: 39] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Franchini M, Mannucci PM. The More Recent History of Hemophilia Treatment. Semin Thromb Hemost. [DOI: 10.1055/s-0042-1756188] [Reference Citation Analysis]
2 Prezotti ANL, Frade-guanaes JO, Yamaguti-hayakawa GG, Ozelo MC. Immunogenicity of Current and New Therapies for Hemophilia A. Pharmaceuticals 2022;15:911. [DOI: 10.3390/ph15080911] [Reference Citation Analysis]
3 Ozelo MC, Yamaguti‐hayakawa GG. Impact of novel hemophilia therapies around the world. Res Pract Thromb Haemost 2022;6. [DOI: 10.1002/rth2.12695] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Hermans C, Reding MT, Astermark J, Klamroth R, Mancuso ME. Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: a critical review from the physician's perspective. Critical Reviews in Oncology/Hematology 2022. [DOI: 10.1016/j.critrevonc.2022.103678] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Müller J, Miesbach W, Prüller F, Siegemund T, Scholz U, Sachs UJ; Standing Commission Labor (STAEKOLA) of the Society of Thrombosis and Haemostasis Research (GTH). An Update on Laboratory Diagnostics in Haemophilia A and B. Hamostaseologie 2022. [PMID: 35104901 DOI: 10.1055/a-1665-6232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Klamroth R, Hampton K, Saulyte Trakymienė S, Korsholm L, Carcao M. Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP). Patient Prefer Adherence 2021;15:2443-54. [PMID: 34764641 DOI: 10.2147/PPA.S326282] [Reference Citation Analysis]
7 Mancuso ME, Biss T, Fischer K, Maas Enriquez M, Steele M, Wang M, Tseneklidou-Stoeter D, Ahuja S, Kenet G. PROTECT VIII kids extension study: Long-term safety and efficacy of BAY 94-9027 (damoctocog alfa pegol) in children with severe haemophilia A. Haemophilia 2021;27:434-44. [PMID: 33724632 DOI: 10.1111/hae.14294] [Reference Citation Analysis]
8 Napolitano M, Olsen AA, Nøhr AM, Eichler H. Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C. J Blood Med 2021;12:9-20. [PMID: 33536803 DOI: 10.2147/JBM.S284060] [Reference Citation Analysis]
9 Zadeh Mehrizi T, Mousavi Hosseini K. An overview on the investigation of nanomaterials' effect on plasma components: immunoglobulins and coagulation factor VIII, 2010–2020 review. Nanoscale Adv 2021;3:3730-45. [DOI: 10.1039/d1na00119a] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Šaulytė Trakymienė S, Economou M, Kenet G, Landorph A, Shen C, Kearney S. Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5. J Thromb Haemost 2020;18 Suppl 1:15-25. [PMID: 32940955 DOI: 10.1111/jth.15036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Matsushita T, Mangles S. An overview of the pathfinder clinical trials program: Long-term efficacy and safety of N8-GP in patients with hemophilia A. J Thromb Haemost 2020;18 Suppl 1:26-33. [PMID: 32558236 DOI: 10.1111/jth.14958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Giangrande P, Abdul Karim F, Nemes L, You CW, Landorph A, Geybels MS, Curry N. Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2. J Thromb Haemost 2020;18 Suppl 1:5-14. [PMID: 32544297 DOI: 10.1111/jth.14959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Firrman J, Wang Q, Wu W, Dong B, Cao W, Moore AR, Roberts S, Konkle BA, Miao C, Liu L, Li D, Xiao W. Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII. Mol Ther Methods Clin Dev 2020;17:328-36. [PMID: 32071925 DOI: 10.1016/j.omtm.2019.12.019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Morfini M, Marchesini E. The availability of new drugs for hemophilia treatment. Expert Rev Clin Pharmacol 2020;13:721-38. [PMID: 32515633 DOI: 10.1080/17512433.2020.1776109] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Tosetto A, Neff A, Lentz SR, Santagostino E, Nemes L, Sathar J, Meijer K, Chowdary P, Shen C, Landorph A, Hampton K. Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials. Haemophilia 2020;26:450-8. [PMID: 32293786 DOI: 10.1111/hae.13980] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
16 Santagostino E, Kenet G, Fischer K, Biss T, Ahuja S, Steele M. PROTECT VIII Kids: BAY 94-9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A. Haemophilia 2020;26:e55-65. [PMID: 32212300 DOI: 10.1111/hae.13963] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
17 Bjørnsdottir I, Støvring B, Søeborg T, Jacobsen H, Sternebring O. Plasma Polyethylene Glycol (PEG) Levels Reach Steady State Following Repeated Treatment with N8-GP (Turoctocog Alfa Pegol; Esperoct®). Drugs R D 2020;20:75-82. [PMID: 32152818 DOI: 10.1007/s40268-020-00297-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Moncalvo F, Martinez Espinoza MI, Cellesi F. Nanosized Delivery Systems for Therapeutic Proteins: Clinically Validated Technologies and Advanced Development Strategies. Front Bioeng Biotechnol 2020;8:89. [PMID: 32117952 DOI: 10.3389/fbioe.2020.00089] [Cited by in Crossref: 17] [Cited by in F6Publishing: 29] [Article Influence: 8.5] [Reference Citation Analysis]
19 Mannucci PM. Hemophilia therapy: the future has begun. Haematologica 2020;105:545-53. [PMID: 32060150 DOI: 10.3324/haematol.2019.232132] [Cited by in Crossref: 33] [Cited by in F6Publishing: 61] [Article Influence: 16.5] [Reference Citation Analysis]
20 Aledort L, Mannucci PM, Schramm W, Tarantino M. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus 2019;17:479-86. [PMID: 31846611 DOI: 10.2450/2019.0211-19] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
21 Ezban M, Hansen M, Kjalke M. An overview of turoctocog alfa pegol (N8-GP; ESPEROCT® ) assay performance: Implications for postadministration monitoring. Haemophilia 2020;26:156-63. [PMID: 31809565 DOI: 10.1111/hae.13897] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
22 Klamroth R, Feistritzer C, Friedrich U, Lentz SR, Reichwald K, Zak M, Chowdary P. Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1). J Thromb Haemost 2020;18:341-51. [PMID: 31618804 DOI: 10.1111/jth.14660] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
23 Hegemann I, Koch K, Clausen WHO, Ezban M, Brand-Staufer B. Evaluation of N8-GP Activity Using a One-Stage Clotting Assay: A Single-Center Experience. Acta Haematol 2020;143:504-8. [PMID: 31639805 DOI: 10.1159/000503377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
24 Tiefenbacher S, Clausen WHO, Hansen M, Lützhøft R, Ezban M. A field study evaluating the activity of N8-GP in spiked plasma samples at clinical haemostasis laboratories. Haemophilia 2019;25:893-901. [PMID: 31294905 DOI: 10.1111/hae.13813] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
25 Shah A, Solms A, Wiegmann S, Ahsman M, Berntorp E, Tiede A, Iorio A, Mancuso ME, Zhivkov T, Lissitchkov T. Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Ann Hematol 2019;98:2035-44. [PMID: 31236667 DOI: 10.1007/s00277-019-03747-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
26 Chowdary P, Carcao M, Holme PA, Jiménez-Yuste V, Lentz SR, Møss J, Poulsen LH, Shen C, Tosetto A, Wheeler A, Santagostino E. Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A. Res Pract Thromb Haemost 2019;3:542-54. [PMID: 31294338 DOI: 10.1002/rth2.12220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
27 Yu JK, Iorio A, Edginton AN; WAPPS co‐investigators. Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. Res Pract Thromb Haemost 2019;3:528-41. [PMID: 31294337 DOI: 10.1002/rth2.12204] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
28 Kearney S, Raffini LJ, Pham TP, Lee XY, von Mackensen S, Landorph A, Takedani H, Oldenburg J. Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII. Patient Prefer Adherence 2019;13:497-513. [PMID: 31040652 DOI: 10.2147/PPA.S196103] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
29 Mahlangu JN. Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B. Ther Adv Hematol 2018;9:335-46. [PMID: 30364483 DOI: 10.1177/2040620718802606] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
30 DiMichele DM. Navigating Speed Bumps on the Innovation Highway in Hemophilia Therapeutics. Hemasphere 2018;2:e144. [PMID: 30887008 DOI: 10.1097/HS9.0000000000000144] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
31 Graf L. Extended Half-Life Factor VIII and Factor IX Preparations. Transfus Med Hemother 2018;45:86-91. [PMID: 29765290 DOI: 10.1159/000488060] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 8.5] [Reference Citation Analysis]
32 Zhang W, Mao JH. [Advances of hemophilia A treatment]. Zhonghua Xue Ye Xue Za Zhi 2018;39:83-6. [PMID: 29551046 DOI: 10.3760/cma.j.issn.0253-2727.2018.01.023] [Reference Citation Analysis]